Pharmafile.com’s top 10 news stories of the week
pharmafile | April 30, 2021 | News story | Medical Communications | COVID-19, covid 19 news, covid-19 news, news roundup, pharma, pharma news
Among our top 10 stories this week: In COVID news, an app has revealed the most common side effects for COVID-19 vaccines, while a PHE study has shown that a single dose of a vaccine can cut transmissions in half. Elsewhere, Sanofi’s RSV drug has shown Phase III clinical trial success.
1. COVID Symptom Study app reveals most common vaccine side effects – Published 28/04/21
An analysis of over 600,000 people’s vaccine reports has been published in The Lancet Infectious Diseases journal, in the largest real-life study of COVID-19 vaccine side-effects in the world.
2. Sanofi’s RSV drug sees Phase III clinical trial success – Published 26/04/21
Sanofi have announced positive topline results from the Phase III MELODY trial into nirsevimab, which demonstrated protection against respiratory syncytial virus (RSV) disease in healthy infants.
3. Single dose of COVID vaccine can cut transmissions in half – Published 28/04/21
A Public Health England (PHE) study into the Pfizer-BioNTech and Oxford-AstraZeneca vaccines has found that a single dose of either jab can cut COVID-19 transmissions by up to half.
4. LEO Pharma receives positive CHMP opinion for dermatitis treatment – Published 26/04/21
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting a marketing authorisation of Leo Pharma’s Adtralza (tralokinumab) for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy.
5. Takeda’s lung cancer drug granted FDA priority review – Published 29/04/21
The FDA has granted priority review for Takeda’s New Drug Application (NDA) for its mobocertinib drug for the treatment of patients with metastatic non-small cell lung cancer (mNSCLC).
6. Researchers find possible new treatment for several cancers – Published 23/04/21
Researchers at The Institute of Cancer Research (ICR) in London have discovered a new use for an ovarian and breast cancer drug that could make it effective against multiple other cancers, including a common form of kidney cancer.
7. European Commission sues AstraZeneca over COVID-19 jab supplies – Published 27/04/21
The European Commission (EC) announced yesterday that it was suing AstraZeneca for failing to respect its contract to supply COVID-19 vaccines to EU countries.
8. Calliditas’ kidney disease drug granted priority review by FDA – Published 28/04/21
The FDA has granted priority review for the New Drug Applicaton (NDA) for Calliditas Therapeutics’ Nefecon, for the treatment of IgA nephropathy (IgAN) – a disease that causes damage to kidney tissues.
9. Lonza to invest over £150 million on new molecule complex – Published 23/04/21
Lonza have announced the construction of a new small molecule manufacturing complex at its Visp site in Switzerland, which will cost CHF 200 million (Swiss franc) to build.
10. NICE to join GetReal Institute alongside nine key healthcare players – Published 28/04/21
NICE has announced it will join with nine other organisations to form the GetReal Institute, a not-for-profit multi-stakeholder enterprise, as a founding member.
Related Content
AstraZeneca shares results from phase 3 trial of COVID-19 prevention drug
AstraZeneca has announced positive high-level results from the SUPERNOVA phase 3 trial for a COVID-19 …
Sanofi and Novavex sign exclusive $1.2bn licensing agreement to co-commercialise COVID-19 vaccine and develop flu-COVID-19 vaccines
French pharma and healthcare company Sanofi and US biotech Novavex, have entered into a co-exclusive …
AstraZeneca withdraws COVID-19 vaccine Vaxzevria
UK-based pharmaceutical company AstraZeneca has announced that is it voluntarily withdrawing its COVID-19 vaccine Vaxzevria …
